Systemic and exhaled cytokine and chemokine profiles are associated with the development of bronchiolitis obliterans syndrome

Journal of Heart and Lung Transplantation

Volumn 29, Issue 9, 2010, Pages 997-1008

  Kastelijn, Elisabeth A ^a   Rijkers, Ger T ^a   Van Moorsel, Coline H M ^a   Zanen, Pieter ^a   Johanna M Kwakkel Van Erp, ^a   Van De Graaf, Ed A ^a   Van Kessel, Diana A ^a   Grutters, Jan C ^a   Van Den Bosch, Jules M M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

BOS; Chemokines; cytokines; Lung transplantation; Serum

Indexed keywords

AZITHROMYCIN; BASILIXIMAB; CHEMOKINE; CORTICOSTEROID; CYTOKINE; EOTAXIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; METHYLPREDNISOLONE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RANTES; TACROLIMUS; VASCULOTROPIN; BIOLOGICAL MARKER; GROWTH PROMOTOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN DERIVATIVE;

ADULT; ARTICLE; BRONCHIOLITIS OBLITERANS; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG MEGADOSE; EXPIRED AIR; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; LONGITUDINAL STUDY; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TH1 CELL; TH2 CELL; BLOOD; BREATH ANALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DRUG COMBINATION; HEART LUNG TRANSPLANTATION; IMMUNOLOGY; MIDDLE AGED; MORTALITY; REFERENCE VALUE; SURVIVAL RATE;

ADULT; BIOLOGICAL MARKERS; BREATH TESTS; BRONCHIOLITIS OBLITERANS; CHEMOKINES; CYSTIC FIBROSIS; CYTOKINES; DRUG THERAPY, COMBINATION; FEMALE; GROWTH SUBSTANCES; HEART-LUNG TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKINS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REFERENCE VALUES; SURVIVAL RATE;

EID: 79952110917     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2010.04.013     Document Type: Article

References (69)

1. Boehler A, Kesten S, Weder W, Speich R. Bronchiolitis obliterans after lung transplantation: a review. Chest 1998;114:1411-26. (Pubitemid 28527420)
2. Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care Med 2002;166:440-4.
3. Verleden GM. Chronic allograft rejection (obliterative bronchiolitis). Semin Respir Crit Care Med 2001;22:551-8.
4. Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007;26:1229-42. (Pubitemid 350256994)
5. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002;21:297-310. (Pubitemid 34224094)
6. Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care Med 2002;166:440-4.
7. Knoop C, Estenne M. Acute and chronic rejection after lung transplantation. Semin Respir Crit Care Med 2006;27:521-33. (Pubitemid 44672555)
8. Nicod LP. Mechanisms of airway obliteration after lung transplantation. Proc Am Thorac Soc 2006;3:444-9. (Pubitemid 44033361)
9. Belperio JA, Lake K, Tazelaar H, Keane MP, Strieter RM, Lynch JP 3rd. Bronchiolitis obliterans syndrome complicating lung or heart-lung transplantation. Semin Respir Crit Care Med 2003;24:499-530. (Pubitemid 37542846)
10. Belperio JA, Weigt SS, Fishbein MC, Lynch JP 3rd. Chronic lung allograft rejection: mechanisms and therapy. Proc Am Thorac Soc 2009;6:108-21.
11. Hodge G, Hodge S, Chambers D, Reynolds PN, Holmes M. Bronchiolitis obliterans syndrome is associated with absence of suppression of peripheral blood Th1 proinflammatory cytokines. Transplantation 2009;88:211-8.
12. Bharat A, Narayanan K, Street T, et al. Early posttransplant inflammation promotes the development of alloimmunity and chronic human lung allograft rejection. Transplantation 2007;83:150-8. (Pubitemid 46185205)
13. Zhai Y, Ghobrial RM, Busuttil RW, Kupiec-Weglinski JW. Th1 and Th2 cytokines in organ transplantation: paradigm lost? Crit Rev Immunol 1999;19:155-72. (Pubitemid 29238705)
14. Beauregard C, Stevens C, Mayhew E, Niederkorn JY. Cutting edge: atopy promotes Th2 responses to alloantigens and increases the incidence and tempo of corneal allograft rejection. J Immunol 2005;174: 6577-81. (Pubitemid 40705616)
15. Keane MP, Gomperts BN, Weigt S, et al. IL-13 is pivotal in the fibro-obliterative process of bronchiolitis obliterans syndrome. J Immunol 2007;178:511-9. (Pubitemid 46033635)
16. Uboldi de CM, Dametto E, Fasano ME, et al. Cytokines and chronic rejection: a study in kidney transplant long-term survivors. Transplantation 2004;77:548-52. (Pubitemid 38282810)
17. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 2001;163:1693-722. (Pubitemid 32578777)
18. Gessner C, Scheibe R, Wotzel M, et al. Exhaled breath condensate cytokine patterns in chronic obstructive pulmonary disease. Respir Med 2005;99:1229-40. (Pubitemid 41245308)
19. Bucchioni E, Kharitonov SA, Allegra L, Barnes PJ. High levels of interleukin-6 in the exhaled breath condensate of patients with COPD. Respir Med 2003;97:1299-302. (Pubitemid 37526998)
20. Wechsler ME, Grasemann H, Deykin A, et al. Exhaled nitric oxide in patients with asthma: association with NOS1 genotype. Am J Respir Crit Care Med 2000;162:2043-7. (Pubitemid 32051661)
21. Montuschi P, Kharitonov SA, Barnes PJ. Exhaled carbon monoxide and nitric oxide in COPD. Chest 2001;120:496-501. (Pubitemid 32881266)
22. Montuschi P, Collins JV, Ciabattoni G, et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000;162:1175-7.
23. Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne EA, Barnes PJ. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994;343:133-5. (Pubitemid 24028638)
24. Stirling RG, Kharitonov SA, Campbell D, et al. Increase in exhaled nitric oxide levels in patients with difficult asthma and correlation with symptoms and disease severity despite treatment with oral and inhaled corticosteroids. Asthma and Allergy Group. Thorax 1998;53:1030-4. (Pubitemid 28567003)
25. Van MA, Knoop C, Estenne M. Early detection of chronic pulmonary allograft dysfunction by exhaled biomarkers. Am J Respir Crit Care Med 2007;175:731-6. (Pubitemid 46536490)
26. Brugiere O, Thabut G, Mal H, et al. Exhaled NO may predict the decline in lung function in bronchiolitis obliterans syndrome. Eur Respir J 2005;25:813-9. (Pubitemid 40667678)
27. Fisher AJ, Gabbay E, Small T, Doig S, Dark JH, Corris PA. Cross sectional study of exhaled nitric oxide levels following lung transplantation. Thorax 1998;53:454-8. (Pubitemid 28308059)
28. Gabbay E, Walters EH, Orsida B, et al. Post-lung transplant bronchiolitis obliterans syndrome (BOS) is characterized by increased exhaled nitric oxide levels and epithelial inducible nitric oxide synthase. Am J Respir Crit Care Med 2000;162:2182-7. (Pubitemid 32051684)
29. Dupont LJ, Dewandeleer Y, Vanaudenaerde BM, Van Raemdonck DE, Verleden GM. The pH of exhaled breath condensate of patients with allograft rejection after lung transplantation. Am J Transplant 2006;6:1486-92. (Pubitemid 44030334)
30. Horvath I, Hunt J, Barnes PJ, et al. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 2005;26:523-48. (Pubitemid 41264218)
31. Singer JD, Willet JB. Applied longitudinal data analysis: modeling change and event occurrence. New York: Oxford University Press; 2003.
32. Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2005;24:1454-9. (Pubitemid 41396439)
33. Kastelijn EA, van Moorsel CH, Rijkers GT, et al. Polymorphisms in the innate immunity associated with the development of BOS after lung transplantation. J Heart Lung Transplant 2010 in press [doi: 10.1016/j.healun.2009.12.013].
34. Mamessier E, Lorec AM, Thomas P, Badier M, Magnan A, Reynaud- Gaubert M. T regulatory cells in stable posttransplant bronchiolitis obliterans syndrome. Transplantation 2007;84:908-16. (Pubitemid 351338953)
35. Lang T, Krams SM, Berquist W, Cox KL, Esquivel CO, Martinez OM. Elevated biliary interleukin 5 as an indicator of liver allograft rejection. Transpl Immunol 1995;3:291-8. (Pubitemid 26046361)
36. Martinez OM, Ascher NL, Ferrell L, et al. Evidence for a nonclassical pathway of graft rejection involving interleukin 5 and eosinophils. Transplantation 1993;55:909-18. (Pubitemid 23122070)
37. Hoffman SA, Wang L, Shah CV, et al. Plasma cytokines and chemokines in primary graft dysfunction post-lung transplantation. Am J Transplant 2009;9:389-96.
38. Davidson C, Verma ND, Robinson CM, et al. IL-13 prolongs allograft survival: association with inhibition of macrophage cytokine activation. Transpl Immunol 2007;17:178-86.
39. Paantjens AW, Kwakkel-van Erp JM, van Ginkel WG, et al. Serum thymus and activation regulated chemokine levels post-lung transplantation as a predictor for the bronchiolitis obliterans syndrome. Clin Exp Immunol 2008;154:202-8.
40. Meyer KC, Cardoni AL, Xiang Z, Cornwell RD, Love RB. Vascular endothelial growth factor in human lung transplantation. Chest 2001; 119:137-43. (Pubitemid 32150558)
41. Tay SS, Plain KM, Bishop GA. Role of IL-4 and Th2 responses in allograft rejection and tolerance. Curr Opin Organ Transplant 2009;14:16-22.
42. Piccotti JR, Chan SY, VanBuskirk AM, Eichwald EJ, Bishop DK. Are Th2 helper T lymphocytes beneficial, deleterious, or irrelevant in promoting allograft survival? Transplantation 1997;63:619-24. (Pubitemid 27132189)
43. Chen N, Gao Q, Field EH. Prevention of Th1 response is critical for tolerance. Transplantation 1996;61:1076-83. (Pubitemid 26120259)
44. Gao Q, Chen N, Rouse TM, Field EH. The role of interleukin-4 in the induction phase of allogeneic neonatal tolerance. Transplantation 1996;62:1847-54. (Pubitemid 27014550)
45. He XY, Chen J, Verma N, Plain K, Tran G, Hall BM. Treatment with interleukin-4 prolongs allogeneic neonatal heart graft survival by inducing T helper 2 responses. Transplantation 1998;65:1145-52. (Pubitemid 28224329)
46. Ke B, Shen XD, Lassman CR, Gao F, Busuttil RW, Kupiec-Weglinski JW. Cytoprotective and antiapoptotic effects of IL-13 in hepatic cold ischemia/reperfusion injury are heme oxygenase-1 dependent. Am J Transplant 2003;3:1076-82. (Pubitemid 37064546)
47. Ke B, Ritter T, Kato H, et al. Regulatory cells potentiate the efficacy of IL-4 gene transfer by up-regulating Th2-dependent expression of protective molecules in the infectious tolerance pathway in transplant recipients. J Immunol 2000;164:5739-45. (Pubitemid 30389816)
48. Sriram U, Biswas C, Behrens EM, et al. IL-4 suppresses dendritic cell response to type I interferons. J Immunol 2007;179:6446-55.
49. Webb DC, Cai Y, Matthaei KI, Foster PS. Comparative roles of IL-4, IL-13, and IL-4Ralpha in dendritic cell maturation and CD4- Th2 cell function. J Immunol 2007;178:219-27. (Pubitemid 46033604)
50. Fujisawa T, bu-Ghazaleh R, Kita H, Sanderson CJ, Gleich GJ. Regulatory effect of cytokines on eosinophil degranulation. J Immunol 1990;144:642-6. (Pubitemid 20036096)
51. de Groen PC, Kephart GM, Gleich GJ, Ludwig J. The eosinophil as an effector cell of the immune response during hepatic allograft rejection. Hepatology 1994;20:654-62. (Pubitemid 24271275)
52. Nolan CR, Saenz KP, Thomas CA, III, Murphy KD. Role of the eosinophil in chronic vascular rejection of renal allografts. Am J Kidney Dis 1995;26:634-42.
53. Le MA, Flamand V, Demoor FX, et al. Critical roles for IL-4, IL-5, and eosinophils in chronic skin allograft rejection. J Clin Invest 1999; 103:1659-67. (Pubitemid 29534360)
54. Goldman M, Le MA, Braun M, Flamand V, Abramowicz D. A role for eosinophils in transplant rejection. Trends Immunol 2001;22:247-51. (Pubitemid 32667511)
55. Johnson TR, Rothenberg ME, Graham BS. Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4- T cells in mice immunized with respiratory syncytial virus G glycoprotein. J Leukoc Biol 2008;84:748-59.
56. Emad A, Emad Y. Relationship between eosinophilia and levels of chemokines (CCL5 and CCL11) and IL-5 in bronchoalveolar lavage fluid of patients with mustard gas-induced pulmonary fibrosis. J Clin Immunol 2008;28:298-305.
57. Yamada H, Yamaguchi M, Yamamoto K, et al. Eotaxin in induced sputum of asthmatics: relationship with eosinophils and eosinophil cationic protein in sputum. Allergy 2000;55:392-7. (Pubitemid 30183060)
58. Malmstrom NK, Kallio EA, Rintala JM, et al. Vascular endothelial growth factor in chronic rat allograft nephropathy. Transpl Immunol 2008;19:136-44.
59. Brown KR, England KM, Goss KL, Snyder JM, Acarregui MJ. VEGF induces airway epithelial cell proliferation in human fetal lung in vitro. Am J Physiol Lung Cell Mol Physiol 2001;281:L1001-10.
60. Krebs R, Tikkanen JM, Nykanen AI, et al. Dual role of vascular endothelial growth factor in experimental obliterative bronchiolitis. Am J Respir Crit Care Med 2005;171:1421-9. (Pubitemid 40800516)
61. Doherty T, Broide D. Cytokines and growth factors in airway remodeling in asthma. Curr Opin Immunol 2007;19:676-80. (Pubitemid 350236803)
62. Broide DH. Immunologic and inflammatory mechanisms that drive asthma progression to remodeling. J Allergy Clin Immunol 2008;121: 560-70. (Pubitemid 351323873)
63. Lee CG, Link H, Baluk P, et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med 2004;10:1095-103. (Pubitemid 39424871)
64. Wen FQ, Liu X, Manda W, et al. TH2 Cytokine-enhanced and TGFbeta- enhanced vascular endothelial growth factor production by cultured human airway smooth muscle cells is attenuated by IFN-gamma and corticosteroids. J Allergy Clin Immunol 2003;111:1307-18. (Pubitemid 36683687)
65. Corne J, Chupp G, Lee CG, et al. IL-13 stimulates vascular endothelial cell growth factor and protects against hyperoxic acute lung injury. J Clin Invest 2000;106:783-91.
66. Boehler A, Estenne M. Obliterative bronchiolitis after lung transplantation. Curr Opin Pulm Med 2000;6:133-9.
67. Rosias PP, Robroeks CM, Kester A, et al. Biomarker reproducibility in exhaled breath condensate collected with different condensers. Eur Respir J 2008;31:934-42.
68. Zheng L, Walters EH, Ward C, et al. Airway neutrophilia in stable and bronchiolitis obliterans syndrome patients following lung transplantation. Thorax 2000;55:53-9. (Pubitemid 30248779)
69. Riise GC, Williams A, Kjellstrom C, Schersten H, Andersson BA, Kelly FJ. Bronchiolitis obliterans syndrome in lung transplant recipients is associated with increased neutrophil activity and decreased antioxidant status in the lung. Eur Respir J 1998;12:82-8. (Pubitemid 28325658)